Since up to 60% of MS patients carry DRB1*15 and some 30% carry DRB1*04, and since the risk of high titer NAbs is increased several times (ORs 3–4) in carriers of respective risk alleles, it may well be relevant to base treatment decisions on HLA genotype. Here, HLA-DRB1 is linked to myeloid sarcoma.